Key takeaways

• Artificial intelligence (AI) offers major opportunities to improve health care, however, current use is fragmented.
• To facilitate the uptake of AI in cardiovascular care, the European Cardiovascular Health Data and AI Network (CHAIN) has been launched, co-funded by the EU4Health Programme, with €20 million in EU funding and coordinated by the European Society of Cardiology.
• This 36-month project aims to build a federated ecosystem for the safe, effective and scalable adoption of AI to improve the prevention, early detection and treatment of cardiovascular and related non-communicable diseases.
• A repository of validated AI solutions with ‘AI passports’ will be created, helping healthcare authorities and professionals to know which models to trust.
• To test the new framework, six real-world use cases will be assessed across different healthcare settings in 13 countries, covering risk stratification, early disease detection, clinical decision support and the management of complex diseases.

Sophia Antipolis, France – 7 October 2026: A new EU-funded flagship initiative to harness the power of health data and artificial intelligence (AI) across the continuum of cardiovascular care has been launched, with funding from the EU4Health Programme.

Cardiovascular diseases (CVDs) remain the leading cause of mortality and disability in Europe, constituting the primary burden among non-communicable diseases (NCDs), with persistent inequalities across countries and institutions. Health data and AI offer major opportunities to improve CVD prevention, early detection and care. However, uptake is currently fragmented and standardised validation mechanisms are lacking.

The European Cardiovascular Health Data and AI Network (CHAIN) has been launched to close the gap, focusing on implementation, evaluation, governance and scale-up. This 36-month project is coordinated by the European Society of Cardiology (ESC) as part of a multi-stakeholder consortium from 20 European countries. The 53 partners include universities and research centres, hospitals and clinical networks, technology companies, national ministries of health and patient organisations. CHAIN builds on the ESC’s EuroHeart registry network, which already unifies 18 ESC member countries with standardised data on cardiovascular care and outcomes, offering tools and frameworks that help countries monitor outcomes, compare practices and drive sustainable improvements in care.

Professor Cecilia Linde, President of the ESC, from the Karolinska Institute, Sweden, said: “One in three deaths in Europe is caused by CVD and the €282 billion cost to the EU from CVD exceeds the EU’s annual budget. The need to act is critical, and CHAIN could not be more timely or important in that endeavour. CHAIN is about turning the promise of AI into better cardiovascular health for everyone. By helping trusted innovations reach patients safely and equitably, we can prevent disease earlier and give more people the opportunity to live longer, healthier lives.”

Professor Folkert Asselbergs, CHAIN Scientific Coordinator and Chair of the ESC AI Gateway, from the Amsterdam University Medical Centre, The Netherlands, said: “In this era of misinformation, patients and healthcare professionals are looking to medical societies like the ESC to lead the way: to provide a framework for the implementation of trusted solutions that really add value beyond what is currently available.”

The aim of CHAIN is to build a federated ecosystem, aligned with the European Health Data Space (EHDS), for the safe, effective and scalable adoption of AI and health data for the improved management of CVDs and related non-communicable diseases. In concrete terms, this means securely connecting hospitals, health data hubs and disease registries across Europe, that will enable AI solutions to be tested, validated and deployed at scale. As a result, healthcare professionals will be able to identify disease earlier, make more informed decisions, and deliver more consistent care to patients.

The federated ecosystem is fundamental to the implementation of the EU Safe Hearts Plan, in particular its flagship initiative on innovation and integration of AI and digital technologies in cardiovascular healthcare.

The launch of CHAIN comes at a time when the European Health Data Space (EHDS), the AI Act, and the evolving EU regulatory framework for medical products, including pharmaceutical, medical devices and in vitro diagnostic legislation, are reshaping how AI is developed, evaluated and deployed in healthcare across Europe. CHAIN will build on and seek synergies with other major EU initiatives, including EUCAIM, COMPASS AI, AI4HF, DataTools4Heart, EHDEN, JACARDI, TEHDAS2 and Xt-EHR, helping to maximise complementarities and impact.

Validated AI tools will be made available through a European repository, supported by AI Passports that document their performance, safety and suitability for clinical use. Together, these resources will help build trust in AI by providing hospitals, healthcare authorities and professionals with clear evidence on which solutions work, for whom and in which clinical settings.

To demonstrate the approach in practice, six real-world use cases will be implemented across 13 countries, covering prevention, early detection, clinical decision support and the management of complex cardiovascular conditions.

Olivér Várhelyi, EU Commissioner for Health and Animal Welfare said; “The question is no longer simply what AI can do. The question is how we make it work safely and effectively for patients and health professionals in everyday healthcare. This is where CHAIN can make a real difference.” 

Professor Asselbergs concluded; “Over the next three years, we hope to create a strategic roadmap for scaling AI adoption in cardiology across Europe. The infrastructure and standards will benefit research and industry, and the validated decision-support tools will help reduce the burden on healthcare systems. Ultimately, the availability of trustworthy tools should translate into earlier, more accurate diagnosis and safer, personalised care for patients.”

ENDS